Small Cell Lung Cancer
- References
1.American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society. 2019. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf.
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.J Clin Oncol. 2006;24(28):4539-4544.
3. Breitling LP, Rinke A, Gress TM. Recent survival trends in high-grade neuroendocrine neoplasms and lung cancer. Neuroendocrinology. 2020;110(3-4):225-233.
4. Abdel-Rahman O. Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a SEER database analysis. Clin Respir J. 2018;12(3):1093-1099.
5.Globocan: https://gco.iarc.who.int/media/globocan/factsheets/populations/818-egypt-fact-
sheet.pdf
6.ESMO:https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-lung-and-chest-
tumours
7.NCCN: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462
8.NICE : https://www.nice.org.uk/what-nice-does/our-guidance/about-nice-guidelines
9.Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small
cell lung carcinoma: a prospective study. Neurology 2015;85(3):235-239.
10.Seute T, Leffers P, ten Velde GP, et al. Detection of brain metastases from small cell lung
cancer: consequences of changing imaging techniques (CT versus MRI). Cancer. 2008;112(8):1827-1834.
11.Martucci F, Pascale M, Valli MC, et al. Impact of (18)F-FDG PET/CT in staging patients
with small cell lung cancer: a systematic review and meta-analysis. Front Med (Lausanne). 2019;6:336.
12.Manoharan P, Salem A, Mistry H, et al. (18)F-Fludeoxyglucose PET/CT in SCLC:
analysis of the CONVERT randomized controlled trial. J Thorac Oncol. 2019;14(7):1296-1305.
13.Qin J, Lu H. Combined small-cell lung carcinoma. Onco Targets Ther
2018;11:3505–3511.
14.Zhao X, Kallakury B, Chahine JJ, et al. Surgical resection of SCLC: prognostic factors
and the tumor microenvironment. J Thorac Oncol. 2019;14(5):914-923.
15.Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery:
proposed definition. Lung Cancer. 2005;49(1):25-33.
16.Ernani V, Ganti AK. Surgery for limited-stage small cell lung cancer: ready for prime-
time? J Thorac Dis. 2017;9(10):3576-3578.
17.Stinchcombe TE. Current treatments for surgically resectable, limitedstage,
and extensive-stage small cell lung cancer. Oncologist. 2017;22(12):1510-1517.
18.Yang CF, Chan DY, Speicher PJ, et al. Role of adjuvant therapy in a population-
based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol. 2016;34(10):1057-1064.
19.Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of
etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30(1):23-36.
20.Karam I, Jiang SY, Khaira M, et al. Outcomes of small cell lung cancer patients treatedwith cisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol. 2015;38(1):51-54.
21. Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemo radiotherapy in patients with limited-stage small cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116-1125.
22. Gomes F, Faivre-Finn C, Mistry H, et al. Safety of G-CSF with concurrent
chemo-radiotherapy in limited-stage small cell lung cancerdsecondary
analysis of the randomised phase 3 CONVERT trial. Lung
Cancer. 2021;153:165-170.
23. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4): 265-271.
24.De Ruysscher D, Lueza B, Le Péchoux C, et al. Impact of thoracic radiotherapy timing in
limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27(10): 1818-1828.
25.Lu H, Fang L, Wang X, et al. A meta-analysis of randomized controlled trials
comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer. Mol Clin Oncol. 2014;2(5):805-810.
26. Kies MS, Mira JG, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol. 1987;5(4):592-600.
27.Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higherdose
prophylactic cranial irradiation (PCI) in patients with limitedstage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol.2009;10(5):467-474.
28.Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation
for patients with small-cell lung cancer in complete remission.
Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl
J Med. 1999;341(7):476-484.
29.Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663-671.
30.Liu ZL, Wang B, Liu JZ, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: a meta-analysis. J Cancer Res Ther. 2018;14(Supplement):S1076-S1083.
31. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized,
phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006;24(13):2044-2051.
32.Lee SM, James LE, Qian W, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poorprognosis small cell lung cancer. Thorax. 2009;64(1):75-80.
33.Slotman BJ, van Tinteren H, Praag JO, et al. Radiotherapy for extensive
stage small-cell lung cancerdauthors’ reply. Lancet. 2015;385(9975):1292-1293.
34.Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation
in extensive small-cell lung cancer. N Engl J Med. 2007;357(7): 664-672.
35.Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17(7):2092-2099.
36.Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy
of second-line chemotherapy in sensitive and refractory smallcell lung cancer. J Thorac Oncol. 2012;7(5):866-872.
37.von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide,
doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658-667.
38.Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23(9):1409-1411.